1. Home
  2. ARI vs AGIO Comparison

ARI vs AGIO Comparison

Compare ARI & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Apollo Commercial Real Estate Finance Inc

ARI

Apollo Commercial Real Estate Finance Inc

HOLD

Current Price

$10.17

Market Cap

1.4B

Sector

Real Estate

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$27.18

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARI
AGIO
Founded
2009
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.6B
IPO Year
2009
2013

Fundamental Metrics

Financial Performance
Metric
ARI
AGIO
Price
$10.17
$27.18
Analyst Decision
Buy
Buy
Analyst Count
4
8
Target Price
$10.83
$36.25
AVG Volume (30 Days)
1.1M
1.5M
Earning Date
02-09-2026
02-12-2026
Dividend Yield
9.91%
N/A
EPS Growth
N/A
N/A
EPS
0.89
N/A
Revenue
$269,296,000.00
$44,791,000.00
Revenue This Year
$23.46
$27.83
Revenue Next Year
$16.03
$134.79
P/E Ratio
$11.38
N/A
Revenue Growth
67.16
36.26
52 Week Low
$7.70
$22.24
52 Week High
$11.11
$46.00

Technical Indicators

Market Signals
Indicator
ARI
AGIO
Relative Strength Index (RSI) 57.80 45.23
Support Level $9.81 $27.30
Resistance Level $10.02 $28.87
Average True Range (ATR) 0.19 1.00
MACD 0.03 0.30
Stochastic Oscillator 95.61 26.55

Price Performance

Historical Comparison
ARI
AGIO

About ARI Apollo Commercial Real Estate Finance Inc

Apollo Commercial Real Estate Finance Inc is a real estate investment trust that primarily originates, invests in, acquires, and manages commercial first-mortgage loans, subordinate financings, commercial mortgage-backed securities, and other real estate-related debt investments. The subordinate loans and first-mortgage loans account for the vast majority of the portfolio on a cost basis. Property types include residential, retail, healthcare, office, mixed-use, hotel, industrial, multifamily, securities, and other, with residential properties and hotels representing the highest property value. More than a third of the properties are located in New York City, with the other properties located across other regions of the United States, as well as other countries.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Share on Social Networks: